Naurex
| Website | www.naurex.com |
|---|
Naurex Inc. is a pharmaceutical company which is developing the drug candidates rapastinel (GLYX-13) and apimostinel (NRX-1074), NMDA receptor modulators, as novel, next-generation antidepressants.[1][2][3]
On July 26, 2015, it was announced that Allergan would be acquiring Naurex for $560 million.[4]
See also
References
- ^ Dolgin, Elie (2013). "Rapid antidepressant effects of ketamine ignite drug discovery". Nature Medicine. 19 (1): 8–8. doi:10.1038/nm0113-8. ISSN 1078-8956. PMID 23295995.
- ^ Hillhouse, Todd M.; Porter, Joseph H. (2015). "A brief history of the development of antidepressant drugs: From monoamines to glutamate". Experimental and Clinical Psychopharmacology. 23 (1): 1–21. doi:10.1037/a0038550. ISSN 1936-2293.
- ^ David T. Yew (6 March 2015). Ketamine: Use and Abuse. Taylor & Francis. pp. 336–. ISBN 978-1-4665-8340-5.
- ^ George Stahl (26 July 2015). "Allergan to Acquire Naurex for $560 Million Cash". The Wall Street Journal.
 | This corporation or company article is a stub. You can help Wikipedia by expanding it. |